Demand for weight-loss drugs highlights key factors for brand owners tackling opportunistic infringers
Shutterstock/Minerva Studio
As Novo Nordisk and Eli Lilly work overtime to meet soaring demand for their popular diabetes and obesity drugs, trademark experts weigh in on what brand owners can do when opportunists take advantage of supply issues.
To read more
Register for free for limited access
Register for free to receive our newsletter, view leading trademark professionals in WTR 1000 and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the WTR experts.
Subscribe now
Already have access? Login below
